BD Advances Iliac Artery Treatment Across the European Union

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has obtained ...

BDX Secures CE Mark for Revello Stent to Treat Iliac Artery Disease

BD wins CE Mark for its Revello vascular covered stent for iliac artery disease, expanding its peripheral vascular portfolio ...

BD (Becton, Dickinson and Company): BD Advances Iliac Artery Treatment Across the European Union

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has obtained ...

Hologic's Diagnostics Strength in Focus: Is More Upside Ahead?

HOLX's Diagnostics unit faces COVID-19 test declines, but Panther Fusion expansion, new assays and AI-driven Genius system support long-term growth potential.

Global Peripheral Vascular Devices Market Poised for Robust Growth at a CAGR of ~6% Through 2032 as Demand for Minimally Invasive Treatments Surges | DelveInsight

Increasing Prevalence of Peripheral Artery Disease (PAD) and Vascular Disorders: A growing global burden of lifestyle-related conditions, such as diabetes, hypertension, obesity, and smoking, has led ...

Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For next session or first session of the day, actually, very ...
The Union Democrat

Mayo Clinic Q&A: Is my racing heart an arrhythmia?

One way to slow a sudden racing heart is by performing a vagal maneuver, which can help interrupt the abnormal rhythm. Vagal maneuvers include bearing down like you are having a bowel movement, ...
MassDevice

BD picks up CE mark for Revello vascular covered stent

BD (NYSE: BDX) announced today that it received CE mark approval for its Revello vascular covered stent system.
Yahoo Finance

BD shares fall by 3% after lowering FY26 profit outlook

Becton Dickinson and Company (BD) has trimmed its fiscal year 2026 (FY26) profit outlook to account for the spin-off of its biosciences & diagnostic solutions business, prompting its share price to ...